SUNLIGHT is a trial that looks at how the drug trifluridine/tipiracil works in combination with bevacizumab and how safe it is when given with bevacizumab versus when given by itself.
Trifluridine/tipiracil is indicated for the treatment of adult patients with metastatic colorectal cancer previously treated with fluoropyrimidine‑, oxaliplatin‑ and irinotecan‑based chemotherapy, an anti‑VEGF biological therapy, and if RAS wild type, an anti‑EGFR therapy.
Trifluridine/tipiracil is an orally active formulation of trifluridine, a thymidine-based nucleoside analog, and tipiracil hydrochloride, a thymidine phosphorylase inhibitor that increases the bioavailability of trifluridine.
The study also uses a drug called bevacizumab, which is an anti-VEGF monoclonal antibody used to treat advanced colorectal cancer, (CRC), advanced non-small cell lung cancer (NSCLC), metastatic breast cancer (MBC) and advanced renal cell cancer.
The use of trifluridine/tipiracil and bevacizumab described here is considered experimental. Preliminary studies of FTD/TPI plus bevacizumab have produced encouraging results in the treatment of refractory metastatic colorectal cancer.